BioMed Research International / 2013 / Article / Tab 3

Review Article

Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives

Table 3

Inhibitory effects of some NS3 helicase inhibitors.

NS3 helicase inhibitorIC50 (μM)References
Helicase
DNARNAATPase

DRBT1.5 500No inhibition[49]
TBBT2060No inhibition[49]
Soluble blue HT40Inhibition23.8[51]
Ring-expanded (fat) nucleoside analogues7–115.5–12Activation[52]
AICAR analogue (compound 4)37No inhibitionND[53]
QU663 , 0.75NDNo inhibition[54]
p140.2NDNo inhibition[55]
DBMTr17.6No inhibitionNo inhibition[56, 57]
Acridone derivatives1.5–20NDNo inhibition[58, 59]
Thiazolpiperazinyl derivative (compound 23)110ND 1000[60]
(BIP)2B5.40.7Inhibition (in the presence of RNA)[61]
Tropolone derivatives3.4–17.8NDND[62]
Tetrahydroacridine derivative, 3a , 0.02NDND[63]
ManoalideND1570[64]
Thioflavin S1012ND[65]
SG1-23-1ND11.7 μg/mLNo inhibition[66]
LOPAC compounds0.6–3.70.8–8.9ND[67]
C-29EAND18.9 μg/mLNo inhibition[68]
Psammaplin AND1732[69]
Cholesterol sulfateND1.7No inhibition[70]

ND: not determined.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.